An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1

AIDS Research and Human Retroviruses

Volumn 13, Issue 12, 1997, Pages 1007-1015

  Binley, James M ^a   Arshad, Homa ^b   Fouts, Timothy R ^a   Moore, John P ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b GONVILLE AND CAIUS COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; UREA; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION; VIRUS NEUTRALIZATION;

EID: 0030792399     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.1007     Document Type: Article

References (48)

1. Inouye S, Hasegawa A, Matsuno S, and Katow S: Changes in antibody avidity after virus infections: Detection by an immunosorbent assay in which a mild protein-denaturing agent is employed. J Clin Microbiol 1984;20:525-529.
2. Polanec J, Seppälä I, Rousseau S, and Hedman K: Evaluation of protein denaturing immunoassays for avidity of immunoglobulin G to rubella virus. J Clin Lab Anal 1994;8:16-21.
3. Thomas HIJ, Wilson S, O'Toole CM, Lister CM, Saeed AM, Watkins RPF, and Morgan-Capner P: Differential maturation of avidity of IgG antibodies to gp41 (p24 and p17), following infection with HIV-1. Clin Exp Immunol 1996;103:185-191.
4. Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements M-L, and Bym RA: Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 1994;8:591-601.
5. Broström C, Sönnerborg A, and Sällberg M: Human immunodeficiency virus type 1-infected patients with no disease progression display high avidity antibody production to autologous V3 sequences. J Infect Dis 1995;171:509-511.
6. Chargelegue D, Colvin BT, and O'Toole CM: A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: Immunoglobulin G titer and avidity are early predictors of clinical course. AIDS (Suppl. 2) 1993;7:S87-S90.
7. Chargelegue D, O'Toole CM, and Colvin BT: A longitudinal study of the IgG antibody response to HIV-1 (p17) Gag protein in HIV-1+ patients with haemophilia: Titre and avidity. Clin Exp Immunol 1993;93:331-336.
8. Chargelegue D, Stanley CM, O'Toole CM, Colvin BT, and Steward MW: The absence or loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1-infected patients. J Infect Dis 1995;172:897-898.
9. Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP, and Murphey-Corb M: Cross protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995;69:2737-2744.
10. Gray JJ: Avidity of EBV VCA-specific IgG antibodies: Distinction between recent primary infection, past infection and reactivation. J Virol Methods 1995;52:95-104.
11. Hedman K, Hietala J, Tiilikainen A, Hartikainen-Sorri A-L, Räihä K, Sunni J, Väanänen P, and Pietiläinen M: Maturation of immunoglobulin G avidity after rubella vaccination studies by an enzyme linked immunosorbent assay (avidity ELISA) and by haemolysis typing. J Med Virol 1989;27:293-298.
12. Hedman K, Lappalainen M, Seppälä I, and Mäkelä O: Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 1989;159:736-740.
13. Hedman K, Salonen E-M, Keski-Oja J, and Räihä K: Recent rubella virus infection indicated by a low avidity of specific IgG. J Clin Immunol 1988;8:214-221.
14. Lew AM, Anders RF, Edwards SJ, and Langford CJ: Comparison of antibody avidity and titer elicited by peptide as a protein conjugate or as expressed in vaccinia. Immunology 1988;65:311-314.
15. MacDonald RA, Hosking CS, and Jones CL: The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988;106:191-194.
16. Meurman O, Waris M, and Hedman K: Immunoglobulin G antibody avidity in patients with respiratory syncytial virus infection. J Clin Microbiol 1992;30:1479-1484.
17. Pullen GR, Fitzgerald GM, and Hosking CS: Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986;86:83-87.
18. Steward MW, Stanley CM, Dimarchi R, Mulcahy G, and Doel TR: High affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot and mouth disease. Immunology 1991;72:99-103.
19. Blank SE, Leslie GA, and Clem W: Antibody affinity and valence in viral neutralization. J Immunol 1972;108:665-673.
20. Hall TJ and Heckel C: Thiocyanate elution estimation of relative antibody avidity. J Immunol Methods 1988;115:153-154.
21. Bata JE, Gyenes L, and Sehon AH: The effect of urea on antibody antigen interactions. Immunochemistry 1964;1:289-293.
22. Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, Ho D, and Moore JP: Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997;71:2799-2809.
23. Koup RA, Safrit JT, Cao Y, Andrews CA, Wu Y, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome. J Virol 1994;68:4650-4655.
24. Moore JP, Cao Y, Ho DD, and Koup RA: Development of the anti gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994;68:5142-5155.
25. Moore JP, Sattentau QJ, Wyatt R, and Sodroski J: Probing the structure of the surface glycoprotein gp120 of human immunodeficiency virus type 1 with a panel of monoclonal antibodies. J Virol 1994;68:469-484.
26. Moore JP and Sodroski J: Antibody cross-competition analysis of the human immunodeficiency virus type 1 exterior envelope glycoprotein. J Virol 1996;70:1863-1872.
27. Poignard P, Fouts T, Naniche D, Moore JP, and Sattentau QJ: Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J Exp Med 1996;183:473-484.
28. Moore JP: Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to sCD4 by ELISA: HIV-2 has a 25-fold lower affinity than HIV-1 for sCD4. AIDS 1990;3:209-219.
29. Moore JP: The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS Res Hum Retroviruses 1993;9:209-219.
30. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton DR, and Ho DD: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
31. Moore JP and Ho DD: Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993;67:863-875.
32. Moore JP and Ho DD: HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS (Suppl. A) 1995;9:S117-S136.
33. Cao Y, Qin L, Zhang L, Safrit J, and Ho DD: Virologie and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl J Med 1995; 332:201-208.
34. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, and Burke DS: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
35. VanCott TC, Bethke FR, Burke DS, Redfield RR, and Birx DL: Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoproteins by candidate AIDS vaccines. J Immunol 1995;155:4100-4110.
36. Kamoun PP: Denaturation of globular proteins by urea: Breakdown of hydrogen or hydrophobic bonds? Trends Biol Sci 1988; 13:424-425.
37. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, and Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-625.
38. Girard M, Kieny M-P, Pinter A, Barré-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Roneo J, Kaczorek M, Gomard E, Gluckman J-C, and Fultz PN: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-546.
39. Bou-Habib KC, Roderiquez G, Oravecz T, Berman PW, Lusso P, and Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
40. VanCott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, and Birx DL: Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV-1. AIDS Res Hum Retroviruses 1995;11:1379-1392.
41. Wrin T and Nunberg JH: HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals. AIDS 1994;8:1622-1623.
42. Broder CC, Earl PL, Long D, Abedon ST, Moss B, and Doms RW: Antigenic implications of HIV-1 envelope quaternary structure: Oligomer-specific and sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994;91:11699-11703.
43. Fouts TR, Binley JM, Trkola A, Robinson JE, and Moore JP: Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997;71:2779-2785.
44. Sattentau QJ and Moore JP: Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the glycoprotein gp120 oligomer. J Exp Med 1995;182:185-196.
45. VanCott TC, Veit SCD, Kalyanaraman V, Earl P, and Birx DL: Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen. J Immunol Methods 1995;183:103-117.
46. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, and Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 showing differing ability to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4828.
47. Sullivan N, Sun Y, Li J, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoprotein from primary and T-cell line passaged human immunodeficiency virus type isolates. J Virol 1995;69:4413-4422.
48. Burton DR, Pyati J, Koduri R, Thornton GB, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Moore JP, Ho DD, and Barbas CF III: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.